WLSI Wellstar International Inc (CE)

Wellstar International, Inc. (OTCBB: WLSI), a provider of specialized diagnostic software and equipment, announced today that its wholly owned subsidiary, Trillennium Medical Imaging ("TMI"), has now joined the fight to quell a growing epidemic among patients in the U.S. that are bed-ridden. Pressure ulcers or decubitus ulcers, commonly known as bedsores, affect hundreds of thousands of patients admitted to healthcare facilities and/or long-term care facilities in the U.S. every year.

The Company's revolutionary thermal imaging system allows nursing staff to objectively identify patterns of injury associated with the development of pressure ulcers, which can lead to an intervention and even prevention of bedsores. According to a recent government report, the number of hospital patients with bedsores has risen dramatically over a 14-year period, leading to longer, more expensive hospital stays. By identifying the tissue changes associated with the development of these wounds prior to skin breakdown, the patient can avoid bedsore occurrences altogether, therefore receiving better care from the nursing staff at these facilities.

Wellstar/TMI CEO John Antonio stated, "We are ready to take this serious epidemic head on. Our team has been aggressively reaching out to educate the caregivers at these facilities regarding our thermal imaging system technology. This is a problem that can be eventually eliminated."

For more information on pressure ulcers, please visit: www.npuap.org and www.bedsores.org

Based on the existing market for TMI's diagnostic system, Wellstar is anticipating revenues in the current year to exceed $16 million.

ABOUT WELLSTAR INTERNATIONAL, INC.

Wellstar International, Inc., through its wholly owned operating subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website by visiting: www.wellstar.us

FORWARD-LOOKING STATEMENTS

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. Specific forward-looking statements contained in this press release include, but are not limited to, the Company's assertion that "based on the existing market for TMI's diagnostic system, Wellstar is anticipating revenues in the current year to exceed $16 million." The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact: Equiti-trend Advisors LLC (800) 953-3350 Toll-Free, U.S. & Canada (858) 436-3350 Local or International